Maraviroc-containing regimen suppresses HIV replication in the cerebrospinal fluid of patients with neurological symptoms.

Authors:
Giovanna Melica
Giovanna Melica
Henri Mondor Hospital
France
Ana Canestri
Ana Canestri
Pitié-Salpêtrière Hospital
France
Gilles Peytavin
Gilles Peytavin
Bichat-Claude Bernard Hospital
Paris | France
Cyril Clavel
Cyril Clavel
IFR30 (CNRS-INSERM-Université Paul Sabatier-CHU de Toulouse)
France
Vincent Calvez
Vincent Calvez
Sorbonne Universités
Anne S Lascaux
Anne S Lascaux
Université Paris XII Creteil
France

AIDS 2010 Aug;24(13):2130-3

Department of Clinical Immunology, Henri Mondor Hospital, Université Paris XII Creteil, Creteil, France.

We report the concentrations of maraviroc in the cerebrospinal fluid (CSF) and plasma of six HIV-1-infected patients with both neurological impairment and detectable HIV-1 replication in CSF. One month after starting maraviroc, the viral load in the CSF decreased significantly (P = 0.005). The median (range) maraviroc concentration in plasma was 347 ng/ml (123-2678). Four patients had CSF concentrations above the protein-adjusted inhibitory concentration (IC90) of 0.57 ng/ml (0.06-10.7) with a median of 102 ng/ml (35-173).

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0b013e32833c9353DOI Listing
August 2010
9 Reads

Publication Analysis

Top Keywords

patients neurological
8
cerebrospinal fluid
8
0005 median
4
decreased 0005
4
median range
4
range maraviroc
4
concentration plasma
4
maraviroc concentration
4
csf decreased
4
load csf
4
replication csf
4
hiv-1 replication
4
detectable hiv-1
4
csf month
4
month starting
4
viral load
4
maraviroc viral
4
plasma 347
4
ng/ml 123-2678
4
ng/ml 006-107
4

Similar Publications